The WHO 'Roll Back Malaria Project': Planning for adverse event monitoring in Africa

Drug Safety

Volumn 28, Issue 4, 2005, Pages 277-286

  Simooya, Oscar ^a  

^a Lulea University of Technology   (Zambia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; ARTEMETHER PLUS BENFLUMETOL; ARTEMISIN; CHLOROQUINE; FANSIDAR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AFRICA; BURUNDI; COMORBIDITY; DEMOCRATIC REPUBLIC CONGO; DRUG LEGISLATION; DRUG RESISTANCE; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; GOVERNMENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; MALARIA; MALNUTRITION; MOZAMBIQUE; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; SOUTHEAST ASIA; TANZANIA; TUBERCULOSIS; UNITED NATIONS; WORKSHOP; WORLD HEALTH ORGANIZATION; ZAMBIA;

ADVERSE DRUG REACTION REPORTING SYSTEMS; AFRICA SOUTH OF THE SAHARA; ANTIMALARIALS; CHILD, PRESCHOOL; HEALTH PLANNING; HUMANS; MALARIA; MOSQUITO CONTROL; PRODUCT SURVEILLANCE, POSTMARKETING;

EID: 17444408489     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200528040-00001     Document Type: Review

References (33)

1. Kachur SP, Bloland PB. Malaria, In: Wallace RB, editor. Maxoy-Rosenau textbook of public health and preventive medicine. 14th ed. Stamford (CT): Appleton and Lange, 1978: 313-48
2. Kevin Baird J. Resurgent malaria at the millennium: control strategies in crisis. Drugs 2000; 59 (4): 719-43
3. Bruce-Chwatt LJ. Essential malariology. London: Heinemann Medical Books, 1980
4. MacDonald G. The epidemiology and control of malaria. London: Oxford University Press, 1957
5. Campbell CC, Chin W, Collins WE, et al. Chloroquine resistant Plasmodium falciparum from East Africa: cultivation and drug sensitivity of the Tanzanian I/CDC strain from an American tourist. Lancet 1979; II: 1151-4
6. Bruce-Chwatt LJ, editor. World Health Organization Monograph Series, No. 27. Geneva: World Health Organization, 1981
7. World Health Organization. The Africa malaria report, 2003 (WHO/CDS/MAL/2003.1093). Geneva: World Health Organization and UNICEF, 2003
8. World Health Organization. The African summit on Roll Back Malaria, Abuja, Nigeria, 25th April 2000 (document WHO/ CDS/RBM/2000.17). Geneva: World Health Organization, 2000
9. Stahel E, Degremont A, Lagler U. Pyrimethamine/sulfadoxine resistant falciparum malaria acquired at Dar Es Salaam, Tanzania. Lancet 1982; I: 1118-9
10. Timmermans PM, Hess V, Jones ME. Pyrimethamine resistant falciparum malaria in East Africa. Lancet 1982; I: 1181
11. World Health Organization. Framework for implementing and updating antimalarial treatment policy in Africa: a guide for malaria control programmes. Harare: World Health Organization Regional Office for Africa, 2000
12. World Health Organization. The use of essential drugs. Geneva: World Health Organization, 2000. WHO technical report series no. 895
13. Hien TT. An overview of the clinical use of artemisinin and its derivatives in the treatment of falciparum malaria in Vietnam. Trans R Soc Trop Med Hyg 1994; 88 Suppl. 1: S5-6
14. Hien TT, Day NP, Nguyen HP, et al. A controlled trial of artemether or quinine in Vietnamese adults with severe falciparum malaria. N Engl J Med 1996; 335: 76-83
15. van Hensbrook MB, Onyiorah E, Jaffar S. A trial of artemether or quinine in children with cerebral malaria. N Engl J Med 1996; 335 (2): 69-75
16. Price R, van Vogt M, Phaipum L, et al. Adverse effects in patients treated with artemisinin derivatives. Am J Trop Med Hyg 1999; 60 (4): 547-55
17. Ribeiro IR, Olliaro P. Safety of artemisinin and its derivatives: a systematic review of published and unpublished clinical trials. Med Trop (Mars) 1998; 58: 50-3
18. Stephens M, Talbot JCC, Routledge PA. Detection of new adverse drug reactions. 3rd ed. London; Macmillan Reference Ltd, 1998
19. World Health Organization. The importance of pharmacovigilance: safety monitoring of medicinal products. Geneva: World Health Organization, 2002
20. World Health Organization. International drug monitoring: the role of the hospital. Geneva: World Health Organization, 1966. WHO technical report series no. 425
21. Uppsala Monitoring Centre. Safety Monitoring of Medicinal Products: guidelines for setting up and running a Pharmacovigilance Centre. Uppsala: The Uppsala Monitoring Centre, 2000
22. Olsson S. The role of the WHO Programme on International Drug Monitoring in coordinating world wide drug safety efforts. Drug Saf 1998; 19 (1): 1-10
23. British Medical Association. Royal Pharmaceutical Society of Great Britain. British National Formulary (No. 45). London: BMA, RPS, 2003
24. Uppsala Monitoring Centre. Dialogue in pharmacovigilance: more effective communication. Uppsala: The Uppsala Monitoring Centre, 2000
25. Einarson TR. Drug related hospital admissions. Ann Pharmacother 1993; 27: 832-40
26. Bates DW, Cullen DJ, Laird N, et al. Incidence of adverse drug events and potential adverse drug events, implications for prevention. JAMA 1995; 274: 29-34
27. Bates DW, Spell N, Cullen DJ, et al. The cost of adverse events in hospitalised patients. JAMA 1997; 277: 307-11
28. Classen DC, Pestonik SL, Evans RS, et al. Adverse events in hospitalized patients: excess length of stay, extra costs and attributable mortality. JAMA 1997; 277: 301-6
29. Pirmohamed M, Breckenridge AM, Kitteringham NR, et al. Adverse drug reactions BMJ 1999; 316: 1295-8
30. Lazarou J, Pomeraz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients, a meta analysis of prospective studies. JAMA 1998; 279: 1200-5
31. Moore N, Lecointre D, Noblet, et al. Frequency and cost of serious adverse drug reactions in a department of general medicine. Br J Clin Pharmacol 1998; 45: 301-8
32. Government of Zambia. National Drug Policy. Lusaka, Zambia: Ministry of Health, 1999
33. Uppsala Monitoring Centre. Uppsala Reports. Uppsala: Uppsala Monitoring Centre, 2004 Jan